文献速递泌尿男性生殖肿瘤

PEACE-1 三期试验中接受或不接受阿比特龙醋酸酯联合泼尼松治疗的新发转移性去势敏感性前列腺癌男性骨密度评估

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial.
PubMed 文献 · Eur J Cancer · 2025-02-06

PEACE-1 三期试验预设分析,评估新发转移性去势敏感性前列腺癌患者在接受雄激素剥夺治疗联合多西他赛基础上加用阿比特龙醋酸酯联合泼尼松是否增加骨丢失。共 97 例接受阿比特龙醋酸酯联合泼尼松、98 例未接受,两组三个部位骨密度均值及平均百分比变化在治疗第一年均下降且组间无差异,24 个月时阿比特龙醋酸酯联合泼尼松组骨质疏松患者数呈数值上两倍增加。

要点

  • 两组腰椎、股骨颈和全髋骨密度均值及平均百分比变化在治疗第一年均下降,组间无差异。
  • 24 个月时阿比特龙醋酸酯联合泼尼松组骨质疏松患者数呈数值上两倍增加。
  • 加用阿比特龙醋酸酯联合泼尼松未显著增加骨丢失。

核心结论

  • 这是首项在随机试验中对使用阿比特龙醋酸酯联合泼尼松的实验性治疗进行骨密度前瞻性评估的研究。
  • 两组均出现快速骨丢失,加用阿比特龙醋酸酯联合泼尼松未显著增加骨丢失,尽管 2 年时观察到骨质疏松发生率数值上更高。

研究设计与样本

  • PEACE-1 三期试验预设分析,研究过程中修订方案以评估加用阿比特龙醋酸酯联合泼尼松是否增加骨丢失。
  • 患者随机接受雄激素剥夺治疗联合多西他赛,加或不加阿比特龙醋酸酯联合泼尼松。
  • 接受阿比特龙醋酸酯联合泼尼松治疗 97 例,未接受 98 例;中位年龄 65 岁;每组各有 69 例 ECOG 评分为 0。
  • 接受与未接受阿比特龙醋酸酯联合泼尼松的患者中位基线体重指数分别为 25.6 和 26.5 kg/m2。
  • 基线时分别有 10% 和 30% 的患者存在骨质疏松和骨量减少。

主要发现

  • 两个治疗组三个解剖部位的骨密度平均 T 值和平均百分比变化在治疗第一年均下降,组间无差异。
  • 24 个月时,阿比特龙醋酸酯联合泼尼松组骨质疏松患者数呈数值上两倍增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Addition of abiraterone acetate plus prednisone (AAP) to androgen deprivation therapy (ADT) with or without docetaxel (D) improved overall survival in patients with de novo metastatic castration sensitive prostate cancer in the PEACE-1 trial. The protocol was amended during the course of the study to assess whether addition of AAP increases bone loss. METHODS: Patients were randomized to receive either ADT + D with or without AAP. Bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip were measured by dual X-ray absorptiometry at baseline, 6, 12, and 24 months (M). T-Scores and mean percent change in BMD values were assessed. RESULTS: With 97 patients treated with AAP and 98 without, the median age was 65 years and 69 patients were ECOG 0 in each arm. Median baseline body mass index was 25.6 and 26.5 kg/m2 in patients treated with or without AAP, respectively. Ten and 30 % presented with baseline osteoporosis and osteopenia, respectively. Mean T scores and mean percent changes in BMD measured on three anatomic sites decreased during the first year of treatment in both arms, without difference between arms. At M24, a numerical two-fold increase in patients with osteoporosis was observed in the AAP arm. CONCLUSIONS: This is the first prospective assessment of BMD in a randomized trial with an experimental treatment using AAP. Bone loss occurred rapidly in both arms, and addition of AAP did not increase bone loss significantly although a numerically higher rate of osteoporosis was observed at 2 years. TRIAL REGISTRATION: NCT01957436.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Roubaud G, Kostine M, McDermott RS, et al. Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial. Eur J Cancer. 2025. PMID: 39923274. doi:10.1016/j.ejca.2025.115293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。